MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC

The results of the phase III MARIPOSA study [1] on overall survival (OS) in untreated patients with EGFR (epidermal growth factor receptor)-mutated (EGFRm) NSCLC, which were presented at ELCC 2025, attracted a great deal of attention.